Ananda Developments PLC Change of Location for General Meeting
October 08 2024 - 5:50AM
RNS Regulatory News
RNS Number : 3672H
Ananda Developments PLC
08 October 2024
ANANDA DEVELOPMENTS
PLC
("Ananda"
or the "Company")
Change of Location for
General Meeting (GM)
Ananda Developments plc (AQSE: ANA),
a life sciences company focused on the research and clinical
development of CBD-based therapies for a range of complex
inflammatory pain conditions, announces that the location of the
upcoming General Meeting (GM), previously scheduled to be held at
2.00pm today at the offices of Shakespeare Martineau LLP, 60 Floor,
60 Gracechurch Street, London EC3V 0HR, has been changed.
Due to unforeseen security concerns and the closure of the current
venue, we have made the decision to move the GM to a new location
to ensure the safety and comfort of all attendees.
The GM will now take place at:
40 Gracechurch Street, London, EC3V 0BT
Date and time of the GM remain unchanged.
We apologise for any inconvenience this may cause and appreciate
your understanding as we prioritize the safety of our shareholders
and stakeholders.
Please ensure that you update your records with the new venue
information. Should you have any questions or require further
assistance, please contact our investor relations team at
ir@anandadevelopments.com.
-Ends-
The Directors of the Company accept
responsibility for the contents of this announcement.
For
more information please contact:
|
InvestorHub
Engage with us directly at Ananda
Developments Investor Hub
|
Sign up at https://investors.anandadevelopments.com/s/a66906
|
|
ANANDA DEVELOPMENTS PLC
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
|
+44 (0)7463 686 497
ir@anandadevelopments.com
|
|
SP
ANGEL CORPORATE FINANCE LLP
Corporate Finance
Richard Morrison
Caroline Rowe
|
+44 (0)20 3470 0470
|
|
Corporate Broking
Abigail Wayne
Rob Rees
|
|
|
Yellow Jersey PR
Charles Goodwin
Zara McKinlay
|
+44 (0)20 3004 9512
|
About Ananda Developments
Ananda is an AQSE-listed company
whose ambition is to be a leading provider of cannabinoid-based
medicines for the treatment of complex, chronic inflammatory pain
conditions.
For further information on the
Company visit https://anandadevelopments.com/ or
sign up at https://investors.anandadevelopments.com/s/a66906.
https://investors.anandadevelopments.com/link/mPqxKr
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NEXUPGQCUUPCUBR
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From Oct 2024 to Nov 2024
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From Nov 2023 to Nov 2024
